Compounds

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof wherein X is N or CH; Q is NR or O; A and A are independently hydrogen or C alkyl or may together form a carbonyl group; R and R are independently hydrogen, halogen, CF, CN, OR, OR, NRR, NRCOR, NRS0R, S0NRR, SOR or C...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HORWELL, DAVID CHRISTOPHER, SCOPES, DAVID IAN CARTER
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof wherein X is N or CH; Q is NR or O; A and A are independently hydrogen or C alkyl or may together form a carbonyl group; R and R are independently hydrogen, halogen, CF, CN, OR, OR, NRR, NRCOR, NRS0R, S0NRR, SOR or C alkyl optionally and independently substituted by one or more of hydroxyl, C alkoxy, halogen or NR R; R 3 is hydrogen, halogen, CF3 or OR 7; R4 is hydrogen, halogen, CF3, OR8, NR8R9, NR8COR10, NR8S02R10 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR 8 R 9; or when R and R are positioned ortho and taken together form -0(CH)O-, where m is 1-3; R is hydrogen or C alkyl optionally substituted by hydroxyl, C alkoxy or NR R; R is hydrogen or C alkyl; R is hydrogen or C alkyl optionally substituted by OR or NRR; R is hydrogen, C alkyl, optionally substituted by hydroxyl or C alkoxy or C alkylphenyl wherein said phenyl group is optionally substituted by one or more substituents selected from halogen, C alkyl, CF, OR, NRR or OCF; or the groups R and R when they are attached to a nitrogen atom may together form a 5- or 6-membered ring which optionally contains one further heteroatom selected from NR, S and O said 5 or 6 membered ring being optionally substituted by hydroxyl or C alkoxy; or the groups R and R when they are attached to a nitrogen atom may together form an azetidinyl ring optionally substituted by hydroxyl or C alkoxy; and R is C alkyl or a phenyl group optionally substituted by one or more substituents selected from halogen, C alkyl, CF, OCF or OR; and n is 1 or 2. The use of the compounds in treating amyloid disease is also disclosed.